Literature DB >> 12203826

Mouse transgenic for murine oviduct-specific glycoprotein promoter-driven simian virus 40 large T-antigen: tumor formation and its hormonal regulation.

Ichiro Miyoshi1, Kazuhiro Takahashi, Yasuhiro Kon, Tadashi Okamura, Yasumasa Mototani, Yoshihiko Araki, Noriyuki Kasai.   

Abstract

Transgenic mice were generated in which a 2.2-kb segment of the 5'-flanking sequence of the mouse oviduct-specific glycoprotein (OGP) gene was used to drive expression of the simian virus 40 large T antigen (Tag). These mice spontaneously developed tumors in the female reproductive tract. Analysis using reverse transcriptase-polymerase chain reaction showed that the 2.2-kb OGP 5'-flanking region drove Tag mRNA expression in the oviduct, uterus, vagina, and ovary, but not in other tissues. Histological and immunohistochemical analyses revealed that the tumor cells were distributed in the oviduct, endometrium, myometrium, and vagina; and had atypical features, abnormal mitosis, and Tag expression. Ovariectomy suppressed Tag expression, and thereby, blocked tumorigenesis in the transgenic mice. Estradiol administration to ovariectomized transgenic mice led to dramatic hyperplasia of the reproductive tract tissues in association with enhanced Tag expression, both in intensity and distribution. These results demonstrated that a 2.2-kb fragment of the 5'-flanking sequence of the mouse OGP gene was capable of directing the expression of Tag and inducing tumorigenesis in female reproductive tract tissues in an estrogen-dependent manner. Estrogen response elements present in the promoter region were functional in vivo. These transgenic mice represent a unique model, since they develop tumors in the oviducts as well as in other tissues derived from the Mullerian duct. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12203826     DOI: 10.1002/mrd.10175

Source DB:  PubMed          Journal:  Mol Reprod Dev        ISSN: 1040-452X            Impact factor:   2.609


  29 in total

Review 1.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

2.  Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis.

Authors:  Ying Wang; Kathy Qi Cai; Elizabeth R Smith; Toni M Yeasky; Robert Moore; Parvin Ganjei-Azar; Andres J Klein-Szanto; Andrew K Godwin; Thomas C Hamilton; Xiang-Xi Xu
Journal:  Mol Cell Biol       Date:  2016-08-26       Impact factor: 4.272

3.  High-grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease.

Authors:  Yali Zhai; Rong Wu; Rork Kuick; Michael S Sessine; Stephanie Schulman; Megan Green; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2017-07-25       Impact factor: 7.996

4.  Mutant p53 expression in fallopian tube epithelium drives cell migration.

Authors:  Suzanne M Quartuccio; Subbulakshmi Karthikeyan; Sharon L Eddie; Daniel D Lantvit; Eoghainín Ó hAinmhire; Dimple A Modi; Jian-Jun Wei; Joanna E Burdette
Journal:  Int J Cancer       Date:  2015-04-11       Impact factor: 7.396

Review 5.  Minireview: animal models and mechanisms of ovarian cancer development.

Authors:  Lisa K Mullany; JoAnne S Richards
Journal:  Endocrinology       Date:  2012-03-06       Impact factor: 4.736

Review 6.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

7.  Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models.

Authors:  Yusuke Kobayashi; Hiroyasu Kashima; Ren-Chin Wu; Jin-Gyoung Jung; Jen-Chun Kuan; Jinghua Gu; Jianhua Xuan; Lori Sokoll; Kala Visvanathan; Ie-Ming Shih; Tian-Li Wang
Journal:  Clin Cancer Res       Date:  2015-06-24       Impact factor: 12.531

8.  Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.

Authors:  Rong Wu; Yali Zhai; Rork Kuick; Anthony N Karnezis; Paloma Garcia; Anum Naseem; Tom C Hu; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2016-11       Impact factor: 7.996

9.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Authors:  Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

10.  A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.

Authors:  Cheryl A Sherman-Baust; Elisabetta Kuhn; Blanca L Valle; Ie-Ming Shih; Robert J Kurman; Tian-Li Wang; Tomokazu Amano; Minoru S H Ko; Ichiro Miyoshi; Yoshihiko Araki; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Patrice J Morin
Journal:  J Pathol       Date:  2014-07       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.